SUPN · Supernus Pharmaceuticals, Inc. · Earnings Call Transcripts & Audio
$42.52
-0.52 (-1.21%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$2.48B
Shares
58.13M
Volume · Oct 1
227.69K
Avg daily vol (3M)
788.96K
Supernus Pharmaceuticals, Inc. Earnings Call Transcripts
Quarterly earnings calls for Supernus Pharmaceuticals, Inc. (SUPN), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲19.5%
$177.35M
$1.75M
'22 Q3
22-11-08
▲5.2%
$167.33M
$25.48M
'22 Q4
23-02-28
▲0.8%
$153.76M
$16.95M
'23 Q1
23-05-09
▼20.3%
$135.56M
−$831,000
'23 Q2
23-07-24
▼13.2%
$153.88M
−$15.98M
'23 Q3
23-10-25
▼1.8%
$164.31M
$1.18M
'23 Q4
24-02-27
▼6.6%
$143.64M
$124,000
'24 Q1
24-04-24
▲24.2%
$168.32M
$19.92M
'24 Q2
24-08-06
▲14.2%
$175.69M
$38.50M
'24 Q3
24-10-21
▲6%
$174.16M
$15.33M
'24 Q4
25-02-11
▲4.3%
$149.82M
−$11.83M
'25 Q1
25-04-23
▼1.7%
$165.45M
$22.50M
'25 Q2
25-07-22
▲9.3%
$192.10M
−$45.12M
'25 Q3
25-10-21
▲21.5%
$211.57M
−$4.11M
'25 Q4
26-02-24
▲38.6%
$207.71M
−$2.29M
'26 Q1
26-05-05
LATEST
▲32.4%
$219.06M
−$58.37M
'26 Q2
26-08-03
Conference
Investor event
2026-08-03
Supernus Pharmaceuticals, Inc. (SUPN) August 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-03
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2026 Earnings Call
Revenue
$219.06M
▲ 32.4% YoY Diluted EPS
$-1.01
▼ 352.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Supernus Pharmaceuticals, Inc. (SUPN) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript
Confident tone
Onapto/Oxtellar XR rebound and second supplier
Quillivant/Kelbree ADHD franchise
Zurzuvae collaboration growth
Revenue
$207.71M
▲ 38.6% YoY Diluted EPS
$-0.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-24
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2025 Earnings Call Transcript
Confident tone
Growth products portfolio
ONAPCO launch and supply
Calvary performance and gross-to-net
Revenue
$211.57M*
▲ 21.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-21
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2025 Earnings Call Transcript
Confident tone
Onapgo launch and supply constraints
Zurzuvae collaboration and women's health
Apomorphine differentiation vs. competitors
Revenue
$192.10M
▲ 9.3% YoY Diluted EPS
$-0.80
▼ 215.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-22
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2025 Earnings Call Transcript
Confident tone
Qelbree growth driver
Financial performance and operating expenses
Sage Therapeutics acquisition and ZURZUVAE
Revenue
$165.45M
▼ 1.7% YoY Diluted EPS
$0.40
▲ 11.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-23
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2025 Earnings Call Transcript
Confident tone
Qelbree growth
Pipeline advancement (SPN-820, SPN-443)
ONAPGO launch
Revenue
$149.82M
▲ 4.3% YoY Diluted EPS
$-0.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-11
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2024 Earnings Call Transcript
Confident tone
Qelbree growth and label update
ONAPGO launch
Corporate development and financial strength
Revenue
$174.16M*
▲ 6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-21
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call Transcript
Confident tone
Qelbree Growth
GOCOVRI Recovery
SPN-817 for Treatment-Resistant Seizures
Revenue
$175.69M
▲ 14.2% YoY Diluted EPS
$0.69
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2024 Earnings Call Transcript
Confident tone
Qelbree growth and gross-to-net
SPN-443 ADHD candidate
Legacy product erosion
Revenue
$168.32M
▲ 24.2% YoY Diluted EPS
$0.36
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-24
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2024 Earnings Call Transcript
Positive tone
Qelbree growth and net sales
Legacy product erosion (Trokendi XR / Oxtellar XR)
Pipeline catalysts (SPN-820, SPN-817, SPN-443)
Revenue
$143.64M
▼ 6.6% YoY Diluted EPS
$0.00
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2023 Earnings Call Transcript
Confident tone
Qelbree growth
Trokendi XR / Oxtellar XR legacy erosion
ADHD market dynamics
Revenue
$164.31M*
▼ 1.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-25
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2023 Earnings Call Transcript
Revenue
$153.88M
▼ 13.2% YoY Diluted EPS
$-0.29
▼ 1066.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-24
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2023 Earnings Call Transcript
Revenue
$135.56M
▼ 20.3% YoY Diluted EPS
$-0.02
▼ 114.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2023 Earnings Call Transcript
Revenue
$153.76M
▲ 0.8% YoY Diluted EPS
$0.29
▼ 32.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2022 Earnings Call Transcript
Revenue
$167.33M*
▲ 5.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2022 Earnings Call Transcript
Revenue
$177.35M
▲ 19.5% YoY Diluted EPS
$0.03
▼ 92.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2022 Earnings Call Transcript
Revenue
$170.05M
▲ 20.3% YoY Diluted EPS
$0.14
▼ 67.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2022 Earnings Call Transcript
Revenue
$152.51M
▲ 16.5% YoY Diluted EPS
$0.43
▲ 290.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2021 Earnings Call Transcript
Revenue
$159.05M*
▲ 10.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-28
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2021 Earnings Call Transcript
Revenue
$148.46M
▼ 4.3% YoY Diluted EPS
$0.40
▼ 45.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2021 Earnings Call Transcript
Revenue
$141.33M
▲ 11.5% YoY Diluted EPS
$0.43
▼ 33.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2021 Earnings Call Transcript
Revenue
$130.93M
▲ 37.9% YoY Diluted EPS
$0.11
▼ 72.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-24
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2020 Earnings Call Transcript
Revenue
$143.56M*
▲ 42.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2020 Earnings Call Transcript
Revenue
$155.13M
▲ 51.9% YoY Diluted EPS
$0.74
▲ 37% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-11
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2020 Earnings Call Transcript
Revenue
$126.73M
▲ 21% YoY Diluted EPS
$0.65
▲ 6.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2020 Earnings Call
Revenue
$94.98M
▲ 11.1% YoY Diluted EPS
$0.40
▲ 17.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-27
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2019 Earnings Call
Revenue
$100.45M
▼ 13.4% YoY Diluted EPS
$0.62
▲ 29.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–29 of 29 earnings calls
Key facts
CIK
1356576
CUSIP
868459108
13F (30d)
12 filings
10 filers
Visit website
Investor relations